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Objective
• To evaluate prostate cancer diagnosis rates and survival
outcomes in patients receiving unrelated (non-prostate)
urological care with those in patients receiving
non-urological care.
Materials and Methods
• We conducted a population-based study using the
Surveillance Epidemiology and End Results (SEER)
database to identify men who underwent surgical
treatment of renal cell carcinoma (RCC; n = 18 188) and
colorectal carcinoma (CRC; n = 45 093) between 1992
and 2008.
• Using SEER*stat software to estimate standardized
incidence ratios (SIRs), we investigated rates of prostate
cancer diagnosis in patients with RCC and patients with
CRC.
• Adjusting for patient age, race and year of diagnosis on
multivariate analysis, we used Cox and Fine and Gray
proportional hazards regressions to evaluate overall and
disease-speciﬁc survival endpoints.
Results
• The observed incidence of prostate cancer was higher in
both the patients with RCC and those with CRC: SIR =
1.36 (95% conﬁdence interval [CI] 1.27–1.46) vs 1.06
(95% CI 1.02–1.11). Adjusted prostate cancer SIRs were
30% higher (P < 0.001) in patients with RCC.
• Overall (hazard ratio = 1.13, P < 0.001) and primary
cancer-adjusted mortalities (sub-distribution Hazard
Ratio (sHR) = 1.17, P < 0.001) were higher in patients
with RCC with no signiﬁcant diﬀerence in prostate
cancer-speciﬁc mortality (sHR = 0.827, P = 0.391).
Conclusion
• Rates of prostate cancer diagnosis were higher in patients
with RCC (a cohort with unrelated urological cancer
care) than in those with CRC. Despite higher overall
mortality in patients with RCC, prostate cancer-speciﬁc
survival was similar in both groups.
• Opportunities may exist to better target prostate cancer
screening in patients who receive non-prostate-related
urological care. Furthermore, urologists should not feel
obligated to perform prostate-speciﬁc antigen screening
for all patients receiving non-prostate-related urological
care.
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Introduction
The survival beneﬁt of mass screening for prostate cancer
with serum PSA testing is controversial and has signiﬁcant
health policy implications. Among the trials investigating
the impact of screening on survival, the two largest and
highest quality studies have reported conﬂicting outcomes
[1,2]. As a result of this uncertainty, there is considerable
variation between the screening recommendations of key
national organizations [3–6], which aﬀect provider
decisions regarding the value of PSA screening [7].While
the National Cancer Collaborative Network, AUA and
American Cancer Society endorse a targeted approach to
PSA screening, several professional organizations do not
support, and some even recommend against, routine PSA
screening [8]. This is largely attributable to concerns that
the improvements in long-term survival are not suﬃcient
to justify mass screening or the potential for treatment
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morbidity. Most recently, the US Preventive Services Task
Force ﬁnalized a revision to a draft statement on PSA
screening with a grade ‘D’ recommendation, concluding with
‘moderate certainty’ that the harms of PSA-based detection
and early intervention exceed the potential beneﬁts
regardless of age, racial or ethnic group, or family history [3].
Although prostate cancer screening by urologists has
remained nearly ubiquitous since the introduction of PSA
testing, the lack of consensus regarding PSA screening is
evidenced by the heterogeneity of practice patterns by
primary care physicians [7]. Yet, the impact of patient
exposure to routine urological care on prostate cancer
diagnosis rates and on prostate cancer-speciﬁc outcomes is
poorly studied.We hypothesized that exposure to a
urologist for non-prostate-related diagnoses signiﬁcantly
increases the likelihood of prostate cancer detection and
sought to understand whether any improvement in cancer
detection improves long-term survival in these individuals.
We compared the incidence of new prostate cancer
diagnoses and survival outcomes for those with either of
two unrelated incident cancers, RCC and colorectal
carcinoma (CRC).Whereas localized RCC is a disease
uniformly treated and followed by urologists in the USA,
patients with localized CRC are not routinely exposed to
urological care. Given the lack of known overlapping
environmental or genetic risk factors between RCC, CRC
and prostate cancer, a diﬀerential rate of prostate cancer
diagnosis between patients with localized RCC and CRC
would most probably be attributable to diﬀerences in
exposure to prostate cancer screening.
Patients and Methods
The Surveillance, Epidemiology and End Results (SEER)
programme of the National Cancer Institute was used to
identify our study population [9]. The SEER programme
collects data on all individuals diagnosed with cancer
residing in several geographically deﬁned regions of the
USA [10]. Male patients with clinically localized RCC and
CRC who underwent surgical treatment of their localized
primary kidney or colon tumour between 1992 and 2008
were identiﬁed from the SEER database, which relies on 13
cancer registries and covers ~14% of the population.We
chose the 13 registries from which data were available for
all years of interest.We did not include newer registries so
as to reduce the potential for confounding by geography
over time. The 13 SEER registries included the San
Francisco-Oakland, Detroit, Seattle Puget Sound, Atlanta,
San Jose Monterey, Los Angeles, rural Georgia and the
Alaska Native Tumor Registry, as well as the states of
Connecticut, Hawaii, Iowa, New Mexico and Utah.
To measure the relative risk for prostate cancer in patients
surgically treated for localized RCC or CRC compared with
the general SEER registry population, we calculated a
standardized incidence ratio (SIR) of prostate cancer
diagnosis (i.e. observed/expected incidence) for patients
with CRC and RCC, along with an exact 95% CI. The
SEER*Stat Multiple Primary-SIR program (version 7.0.4)
was used to calculate the SIRs [9,11]. SIR estimates reﬂect
the increase in the incidence of tumours compared with
what we would expect in the general population after
adjusting for age, race and year of diagnosis. The SIR
estimates were obtained by using the MP-SIR macro in
SEER*Stat. SIRs > 1 indicated that those who underwent
resection for CRC or RCC were at increased risk of
developing prostate cancer as compared with the general
population, while SIRs < 1 suggested that those who
underwent resection for CRC or RCC were at a decreased
risk of developing another type of cancer as compared with
the general population. To assess the generalizability of our
ﬁndings, additional cancer sites (localized disease only)
were added as control groups. These included skin
(excluding basal and squamous), oropharynx, thyroid, lung
and bladder cancers.
To better reﬂect the incidence of de novo prostate cancer
diagnoses in the post-treatment period, only patients who
were diagnosed with prostate cancer > 2 months after the
diagnosis of a primary malignancy (RCC or CRC) were
included in this study. Person-years at risk in the cohort
were accumulated by age groups (35–49, 50–59, 60–69,
70–79 and >80 years) and also analysed according to
follow-up interval (2–5, 6–11, 12– 59, 60–119 and >120
months) to identify potential diﬀerences in screening
patterns.
We estimated cumulative incidence functions using
propensity score-based weighting to adjust for measured
confounders [12]. The cumulative incidence functions [13]
provide estimates of adjusted disease-speciﬁc mortality.We
used Cox proportional hazards regressions to investigate
the variables associated with overall survival and Fine and
Gray proportional hazards regressions [14] to investigate
variables associated with disease-speciﬁc survival.
Diﬀerences in demographic data between groups were
compared using chi-squared and t-tests. Survival analyses
and demographic comparisons were implemented using
STATA version 12 (STATA Corp, College Station, TX, USA);
P values < 0.05 were considered statistically signiﬁcant for
all analyses.
Results
Between 1992 and 2008, 19 188 patients undergoing
surgical treatment for localized RCC and 45 093 patients
undergoing surgical treatment for localized CRC were
identiﬁed from the SEER database. Of these, 4.3% (a total
of 2793 patients; 2031 and 762 patients from the CRC and
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RCC cohorts, respectively) were diagnosed with prostate
cancer. Follow-up data (Table 1) showed a large number of
patients (12 938) who aﬀorded data for 10 years of
follow-up. There were no signiﬁcant diﬀerences observed in
prostate cancer tumour stage between the CRC and RCC
cohorts (P = 0.205). In general, patients with RCC were
younger (median age 60 vs 68 years; P < 0.001) and were
more often African-American (10.4 vs 8.5%; P < 0.001)
than patients with CRC (Table 2). Patients with CRC had
well or moderately diﬀerentiated primary cancer more
often than patients with RCC (73.9 vs 42.4%; P < 0.001).
The observed incidence of prostate cancer was higher than
the expected incidence in both the RCC and CRC cohorts,
which were adjusted for age, race and year of diagnosis in
the SEER*stat analysis (Table 3, SIR = 1.36 [95% CI
1.27–1.46] vs. 1.06 [95% CI 1.02–1.11]). The diﬀerence in
observed risk of prostate cancer diagnosis was ~30% higher
for patients with RCC than for those with CRC (P < 0.001).
This increase in prostate cancer diagnosis was observed
when comparing the RCC cohort with other control patient
cohorts (skin, oropharynx and lung cancers; Table 3, all P <
0.01). In patients with localized bladder cancer, another
urological malignancy, a statistically similar elevation in the
rate of prostate cancer diagnosis as in patients with kidney
cancer was observed (P < 0.01). Interestingly, patients with
thyroid cancers, a cancer with high rates of overdiagnosis
[15], also displayed unusually high rates of newly diagnosed
prostate cancer (Table 3).
Diﬀerences in the patterns of prostate cancer diagnosis
were observed when RCC and CRC groups were stratiﬁed
by follow-up interval (Table 4) and age at diagnosis
(Table 5). At a follow-up interval of 2–5 months, the
observed prostate cancer diagnosis was signiﬁcantly higher
than expected in both the CRC and RCC cohorts, while
only patients with RCC had a higher than expected
observed prostate cancer diagnosis at 6–11, 12–59 and >120
months of follow-up. Observed prostate cancer diagnoses
were higher than expected values in both the CRC and
RCC cohorts in the 70–79 years age group. In comparison,
in patients aged 50– 70 years, only patients with RCC had a
higher than expected observed incidence of prostate cancer.
Multivariable analyses were performed to evaluate overall
and disease-speciﬁc survival endpoints. Adjusting for age,
race and year of diagnosis, no signiﬁcant diﬀerence in
prostate cancer-speciﬁc survival was observed between
the RCC and CRC cohorts (sHR = 0.83, P = 0.39). A
subanalysis of patients with at least 10 years (1992–1998) of
expected follow-up (n = 23 369) also failed to show a
diﬀerence in prostate cancer-speciﬁc survival (sHR = 0.78,
Table 1 Patient follow-up interval stratified by duration.
Duration of follow-up No. of
patients alive
Mortality from
primary cancer
Mortality from
prostate cancer
Other-cause
mortality
Total no.
of patients
0–4.99 years 19 000 4249 55 7 187 30 491
5–9.99 years 13 461 1614 79 4 698 19 852
>10 years 10 530 362 38 2 008 12 938
Total no. of patients 42 991 6225 172 13 893 63 281
Table 2 Descriptive statistics and clinical characteristics of the study cohort.
CRC,N = 45 093 RCC,N = 18 188 P
Age (continuous) <0.001
Mean (SD) 66.5 (12.4) 58.9 (14.0)
Median 68 60
Age (categorical), n (%) <0.001
<35 years 455 (1.0) 644 (3.5)
35–49 years 3 639 (8.1) 3 586 (19.7)
50–59 years 8 678 (19.2) 4 799 (26.4)
60–69 years 12 472 (27.7) 4 871 (26.8)
70–79 years 13 176 (29.2) 3 344 (18.4)
>80 years 6 673 (14.8) 944 (5.2)
Race, n (%) <0.001
White 36 237 (80.0) 14 801 (81.3)
African-American 3 654 (8.5) 1 901 (10.4)
Other 5 202 (11.5) 1 486 (8.1)
Primary tumour grade, n (%) <0.001
Well diﬀerentiated 6 288 (13.9) 2 360 (13.0)
Moderately diﬀerentiated 27 063 (60.0) 7 171 (39.4)
Poor diﬀerentiated 3 659 (8.1) 2 980 (16.4)
Undiﬀerentiated 166 (0.4) 465 (2.6)
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P = 0.34). Furthermore, compared with CRC, those with
RCC had higher primary cancer mortality (sHR = 1.17, P <
0.001) and overall mortality (hazard ratio = 1.13, P < 0.001)
in adjusted models. Figure 1 shows cumulative incidence
curves estimated by propensity score-based weighting. The
curves show that patients with RCC were more likely than
those with CRC to incur mortality from their primary
cancer and from other causes, while exhibiting similar
prostate cancer-speciﬁc mortality (despite 30% higher rates
of prostate cancer diagnosis). Results did not signiﬁcantly
change when multivariable analysis controlled for available
grade and stage data (data not shown).
Discussion
In the context of the ongoing debate over the merits of
PSA-based screening, it is imperative to better understand
the key factors that aﬀect the diagnosis of patients with
prostate cancer. One factor that has received little attention
appears to be exposure to urological care. Our study shows
an increased rate of prostate cancer diagnoses in both
patients with localized CRC and those with RCC than in
individuals with no previously identiﬁed cancers; however,
after adjusting for age, race and year of diagnosis, we
observed a 30% higher rate of prostate cancer diagnosis in
patients with localized RCC than in those with localized
CRC. In the absence of any known genetic or
environmental factors causing patients with RCC to be
more likely to develop prostate cancer than matched
patients with CRC, these results suggest a diﬀerential
probability of prostate cancer detection that is most
probably attributable to the screening practices of the
specialist caring for the patient’s primary malignancy. This
higher-than-expected probability of prostate cancer
diagnoses among patients with RCC held across all age
groups > 50 years. Interestingly, prostate cancer diagnosis
rates were higher than expected in both RCC and CRC
cohorts in patients aged 70–79 years. This ﬁnding is
notable, as elderly patients have been identiﬁed as the
group that appear least likely to beneﬁt from prostate
cancer screening using both population level [16] and
prospective [17] data. Additionally, our identiﬁed RCC
population was more likely to die from unrelated
causes when compared with patients with CRC in a
competing-risks analysis, suggesting the relative increase in
prostate cancer diagnoses among patients with RCC was
not a result of diﬀerences in anticipated life expectancy.
Incorporating available grade and stage data to multivariate
survival analysis has limitations related to missing data and
inconsistencies in stage reporting over time in SEER;
however, an additional analysis comparing RCC and CRC
cohorts, when incorporating available grade and stage data,
did not alter the results for prostate cancer-speciﬁc survival
and overall survival.
To assess whether patterns of prostate cancer diagnosis
seen in CRC and RCC cohorts were generalizable to
patients with other malignancies, rates of prostate cancer
diagnosis in patients who were ﬁrst diagnosed with skin,
oropharynx, thyroid, lung and bladder cancer were
obtained (Table 3). As observed for patients with CRC,
patients diagnosed with skin, oropharynx and lung cancer
were much less likely to be diagnosed with prostate cancer
than patients with RCC. Rates of prostate cancer diagnosis
in patients with bladder cancer – another malignancy
primarily treated by urologists – were similar to those seen
in patients with RCC; however, these results may be
confounded by incidental diagnoses of prostate cancer at
cystoprostatectomy. Interestingly, there was a signiﬁcant
increase in prostate cancer diagnosis in patients diagnosed
Table 3 Standardized incidence ratios of prostate cancer diagnosis in patients diagnosed with cancers of the skin, head and neck, thorax and
abdomen.
Site Median
age, years
Unadjusted
median
survival,
years
Number
observed
prostate
cancer
diagnoses
(% of cohort)
Number
expected
prostate
cancer
diagnoses
(% of cohort)
No. of deaths
from prostate
cancer (%
of cohort)
SIR of
prostate
cancer
diagnosis
(95% CI)
P-value
SIR
Non-visceral
Skin excluding basal and
squamous, n = 40 553
66 16.9 1445 (3.6) 1214 (3.0) 78 (0.19) 1.19 (1.13–1.25) <0.01
Head and neck
Oral cavity and pharynx, n = 8860 67 16.5 328 (3.7) 308 (3.5) 27 (0.3) 1.07 (0.95–1.19) NS
Thyroid, n = 5199 63 16.7 139 (2.7) 103 (2.0) 8 (0.2) 1.34 (1.13–1.59) <0.01
Thorax
Lung and bronchus, n = 13 654 67 10.8 549 (4.0) 483 (3.5) 35 (0.3) 1.14 (1.04–1.24) <0.01
Abdominal
CRC n = 45 093 68 11.6 2031 (4.5) 1911 (4.2) 186 (0.41) 1.06 (1.02–1.11) <0.01
RCC n = 18 188 60 14.2 762 (4.2) 559 (3.0) 30 (0.16) 1.36 (1.27–1.46) <0.01
Bladder n = 49 020 70 12.3 2760 (5.6) 2081 (4.2) 141 (0.3) 1.33 (1.28–1.38) <0.01
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with thyroid cancer. This association was not seen in a
cohort from Sweden where systematic prostate cancer
screening has not been adopted [18]. As such, this
relationship may be explained by the fact that screening for
thyroid and prostate cancer – arguably the two most
overdiagnosed malignancies [15] – may be coupled in
the USA.
Another key ﬁnding in our study was the absence of any
diﬀerences in prostate cancer-speciﬁc mortality between
the RCC and CRC cohorts, even in the large subgroup of
patients (n = 12 938) with >10 years of follow-up (Fig. 1).
Thus, increased detection of prostate cancer in this highly
select group of patients with another malignancy did not
appear to translate into improved prostate cancer-speciﬁc
outcomes. Nevertheless, as has been demonstrated in
prospective randomized screening trials, longer follow-up
may uncover diﬀerences between cohorts that may not
have been evident in the current analysis [2].
The ﬁnding that patients with RCC, who are nearly
uniformly exposed to urological care, have higher rates of
prostate cancer diagnoses is not surprising. Albeit, to our
knowledge, no recent studies have examined PSA screening
patterns among urologists, routine PSA testing by
urologists in men aged < 70 years has historically exceeded
97%, while up to 88% of men aged 70–74 years have
had a PSA test performed [19]. Reasons for such practice
patterns are multifactorial and probably a result of
recommendations from the AUA, strong medico-legal
disincentives for missing a potentially lethal urological
diagnosis, and possibly ﬁnancial and practice-based
incentives [20]. Importantly, patients with CRC were found
to have higher rates of prostate cancer diagnosis only in the
ﬁrst 2–6 months after identiﬁcation of their initial cancer.
This may be partially attributable to the results of DREs
that are performed routinely as a part of the colorectal
evaluation process. Meanwhile, patients treated for localized
RCC were found to have higher than expected rates of
prostate cancer diagnosis at all follow-up time points
(Table 4).
Our ﬁndings lend support to the growing body of evidence
for risk-based prostate cancer screening and treatment
[8,21]. For instance, obtaining a baseline PSA level is
emerging as a useful tool for assessing the risks of
developing prostate cancer and can guide future PSA
screening [8]. Speciﬁcally, the National Comprehensive
Cancer Network guidelines on prostate cancer screening
are now recommending that men obtain a baseline PSA at
age 40 years. Only men with a baseline PSA  1 ng/mL
are then advised to undergo annual PSA screening [7].
Moreover, how the context of a patient’s overall health
informs prostate cancer screening decisions is coming
into better focus. Prognostication of life expectancy,
quantiﬁcation of competing risks of death, and better
understanding of risk factors for developing high-risk
prostate cancer must be balanced and integrated into a
decision to initiate prostate cancer screening [8,21–23].
Furthermore, novel biomarkers for identiﬁcation of
high-risk malignancy, such as the PCA3 assay, hold
signiﬁcant promise [24–26]. As such, future eﬀorts must
continue to focus on helping physicians to better calibrate
prostate cancer screening/treatment policies and practices,
while developing improved clinical algorithms that
minimize overtreatment, but do not hinder eﬀective
intervention for patients who are destined to succumb to
prostate cancer [22,27]. Indeed, the urologist’s role in
appropriately contextualizing the screening, diagnosis and
impact of treatment for prostate cancer to his/her patients
cannot be overstated.
As with any study using an administrative dataset, our
work has limitations.We recognize that the current analysis
is limited by the treatment eﬀects (type of prostate cancer
treatment) that can be examined using the SEER database
and by its retrospective nature. Also, SEER lacks data on
comorbidities, and inferences based on the SIR estimates
might be subject to a healthy survivor eﬀect. Thus, those
patients with RCC or CRC who live long enough to be
diagnosed with prostate cancer may be inherently diﬀerent
from those who die before prostate cancer is detected.
Furthermore, biological and epidemiological associations
between RCC, CRC and prostate cancer may confound our
results; however, no strong evidence to support such a link
exists. In fact, epidemiological data estimating the
prevalence and cumulative incidence of diﬀerent cancers
before prostate cancer diagnosis between matched cohorts
suggest that cancer of the bladder, colon and
Fig. 1 Adjusted cumulative incidence curves controlling for age, race
and year of diagnosis. No significant difference in prostate
cancer-specific survival was observed between the RCC and CRC
groups (sHR = 0.827, P = 0.391). CaP, prostate cancer.
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non-melanoma of the skin are the three most frequently
observed malignancies before prostate cancer diagnosis
[18].When interpreted in the context of our study, these
data strengthen our ﬁndings. This study is further
strengthened by a large patient population, extensive
long-term follow-up in a large subset of patients, and an
analysis that incorporates SIR and multivariable
methodologies.
In summary, in a cohort identiﬁed using SEER data, rates
of prostate cancer diagnoses were signiﬁcantly higher in
patients with localized surgically treated RCC than in those
with localized CRC. This ﬁnding is most probably related
to increased exposure to urological care and suggests
that urologists are closely attuned to the detection of
prostate cancer even when caring for patients with
non-prostate-related diagnoses. Meanwhile, prostate
cancer-speciﬁc survival did not diﬀer between the groups,
even in an analysis restricted to patients with >10 years of
follow-up. Furthermore, these data reveal that opportunities
for better-targeted prostate cancer screening in patients
who receive non-prostate-related urological care appear to
exist.We believe the present study contributes to a growing
body of literature that liberates urologists from being
obligated to perform PSA screening for patients receiving
non-prostate-related care and underscores the need for
better-targeted prostate cancer screening.
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